


IMPLEMENTATION OF A NEW WORK CIRCUIT IN MONOGRAPHY CONSULTATION OF IMMUNE-MEDIATED DISEASES OF THE PHARMACY SERVICE

ALBA MARIA MARTINEZ SOTO; MARIA ONTENIENTE CANDELA ; CARLES INIESTA NAVALON ; PATRICIA ORTIZ FERNANDEZ ; PILAR FERNANDEZVILLACAÑAS FERNANDEZ ; ANABEL HERREROS HERNANDEZ ; GEMMA MARTINEZ SOTO; CARMEN CABALLERO REQUEJO; MAYTE GIL CANDEL; ELENA URBIETA SANZ
*HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA, PHARMACY, MURCIA, SPAIN.

PSQ12305

WHAT WAS DONE?




Implementation of a circuit to improve pharmaceutical care and follow-up pharmacotherapeutic, incorporating the stratification of patients according to the “Model of Stratification and Pharmaceutical Care for diseases Immune-mediated Inflammatory Diseases” (MAPEX) and the use of Patients Reported Outcomes (PROs).


WHY WAS IT DONE?

- Guide the pharmacist in the development of an individualized follow-up strategy for patient evaluating the frequency with which appointments should be established in the consultation of Pharmaceutical Care.
- Use the information from the specific questionnaires to detect possible failures therapeutic.
- Use the results obtained in the PROs to direct the recommendations pharmacotherapeutic to perform, which will be assessed in a multidisciplinary committee of immune-mediated diseases.
- Promote higher quality pharmaceutical care.

HOW WAS IT DONE?




1. Selection of patients to include.




2. Design a database in Access for the collection of stratification data and PROs.



3. Selection of specific and generic PROs.



4. Stratification of active patients according to the MAPEX methodology at the beginning of the implantation and in patients who start during the follow-up period will be stratified at the baseline visit.



5. Establish a strategy for carrying out questionnaires (PROs) in consultation.

WHAT HAS BEEN ACHIEVED?

- An Access database has been created that incorporates the blocks established by the MAPEX model with each of its variables broken down, allowing us to obtain the patient global score.
- 3 pathology-specific PROs have been selected (RAPID3 in rheumatoid arthritis, PSAID12 in Psoriatic Arthritis and BASDAI in Ankylosing Spondylitis) and a generic one, Eurocol-5D-5L.
- The follow-up strategy based on the stratification was selected as the one proposed by the MAPEX model.
- To carry out the PROs, those patients with arthropathies that are were under treatment with biological drugs

WHAT NEXT?

Design a study to measure the results in terms of quality of care obtained with this new circuit.

